337 related articles for article (PubMed ID: 30296685)
21. Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine.
Kong D; Guo S; Yang Y; Guo B; Xie X; Hu W
Bioorg Med Chem Lett; 2019 Mar; 29(6):848-852. PubMed ID: 30685095
[TBL] [Abstract][Full Text] [Related]
22. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
[TBL] [Abstract][Full Text] [Related]
23. Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Liu C; Xu X; Qiu Q; Su X; Dai Y; Yang J; Li H; Shi W; Liao C; Pan M; Huang W; Qian H
Eur J Med Chem; 2017 Sep; 138():458-479. PubMed ID: 28689096
[TBL] [Abstract][Full Text] [Related]
24. Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome.
Li Z; Ren Q; Zhou Z; Cai Z; Wang B; Han J; Zhang L
Eur J Med Chem; 2021 Dec; 225():113807. PubMed ID: 34455359
[TBL] [Abstract][Full Text] [Related]
25. Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
Makadia P; Shah SR; Pingali H; Zaware P; Patel D; Pola S; Thube B; Priyadarshini P; Suthar D; Shah M; Giri S; Trivedi C; Jain M; Patel P; Bahekar R
Bioorg Med Chem; 2011 Jan; 19(2):771-82. PubMed ID: 21215640
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
Liu K; Zhao X; Qi X; Hou DL; Li HB; Gu YH; Xu QL
Eur J Med Chem; 2021 Jun; 218():113388. PubMed ID: 33784603
[TBL] [Abstract][Full Text] [Related]
27. Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
Li Z; Chen Y; Zhang Y; Jiang H; Liu Y; Chen Y; Zhang L; Qian H
Bioorg Chem; 2018 Oct; 80():296-302. PubMed ID: 29980115
[TBL] [Abstract][Full Text] [Related]
28. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
Rudolph J; Chen L; Majumdar D; Bullock WH; Burns M; Claus T; Dela Cruz FE; Daly M; Ehrgott FJ; Johnson JS; Livingston JN; Schoenleber RW; Shapiro J; Yang L; Tsutsumi M; Ma X
J Med Chem; 2007 Mar; 50(5):984-1000. PubMed ID: 17274610
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
Xu Y; Etgen GJ; Broderick CL; Canada E; Gonzalez I; Lamar J; Montrose-Rafizadeh C; Oldham BA; Osborne JJ; Xie C; Shi Q; Winneroski LL; York J; Yumibe N; Zink R; Mantlo N
J Med Chem; 2006 Sep; 49(19):5649-52. PubMed ID: 16970391
[TBL] [Abstract][Full Text] [Related]
30. ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis.
Li Z; Zhou Z; Hu L; Deng L; Ren Q; Zhang L
Pharmacol Res; 2020 Sep; 159():105035. PubMed ID: 32562818
[TBL] [Abstract][Full Text] [Related]
31. Triterpenoids from Hibiscus sabdariffa L. with PPARδ/γ Dual Agonist Action: In Vivo, In Vitro and In Silico Studies.
Giacoman-Martínez A; Alarcón-Aguilar FJ; Zamilpa A; Hidalgo-Figueroa S; Navarrete-Vázquez G; García-Macedo R; Román-Ramos R; Almanza-Pérez JC
Planta Med; 2019 Mar; 85(5):412-423. PubMed ID: 30650453
[No Abstract] [Full Text] [Related]
32. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
[TBL] [Abstract][Full Text] [Related]
33. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
Zhou Y; Wang Y; Zhang L; Tang C; Feng B
Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769
[TBL] [Abstract][Full Text] [Related]
34. A potent free fatty acid receptor 1 agonist with a glucose-dependent antihyperglycemic effect.
Wang X; Xu Y; Feng S; Huang X; Meng X; Chen J; Guo L; Ge J; Zhang J; Chen J; Cheng L; Gu K; Zhang Y; Jiang Q; Ning X
Chem Commun (Camb); 2019 Aug; 55(61):8975-8978. PubMed ID: 31290492
[TBL] [Abstract][Full Text] [Related]
35. MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism.
Kim SH; Hong SH; Park YJ; Sung JH; Suh W; Lee KW; Jung K; Lim C; Kim JH; Kim H; Park KS; Park SG
Sci Rep; 2019 Feb; 9(1):1656. PubMed ID: 30733541
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
[TBL] [Abstract][Full Text] [Related]
38. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases.
Christiansen E; Watterson KR; Stocker CJ; Sokol E; Jenkins L; Simon K; Grundmann M; Petersen RK; Wargent ET; Hudson BD; Kostenis E; Ejsing CS; Cawthorne MA; Milligan G; Ulven T
Br J Nutr; 2015 Jun; 113(11):1677-88. PubMed ID: 25916176
[TBL] [Abstract][Full Text] [Related]
39. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
[TBL] [Abstract][Full Text] [Related]
40. Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Golovanov A; Zozulya S; Zahanich I; Moore D; Tikhonova IG
Eur J Med Chem; 2017 Feb; 127():357-368. PubMed ID: 28076825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
